Paragon pads its exec ranks; Catalent amps up a German plant;

> Contract drug developer Paragon Bioservices has appointed four new vice presidents, following up on its October financing round and plotting to expand its share of the market. More

> Catalent is adding new technology to a German plant focused on softgel manufacturing. News

> BioClinica has added three mid-sized biotechs to its roster of data-management clients. Item

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.